Published in Blood Weekly, May 24th, 1999
These immunotypes - each distinguished by unique signature peptide sequences - are different from the familiar genotypic classification of HIV-1 into subtypes or clades.
"There is every reason to believe that an appropriately constructed and delivered polyvalent HIV vaccine will induce a broad protective response," wrote Susan Zolla-Pazner of Veteran's Affairs Medical Center, New York, and colleagues.
"To construct such a vaccine, it is critical to understand, as completely as possible, the antigenic structure of HIV,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.